ImmunityBio, Inc.
NASDAQ:IBRXBiotechnology
+$0.18 today
- Market cap
- $6.99B
- Beta
- 0.10
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.83
Volume 11.10M
Average 16.40M
Returns on capital
ImmunityBio, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
70.3%
avg 36.7%
ROIC
-56.9%
avg -76.4%
ROA
-70.0%
avg -74.8%
Analysis
ROE is currently the strongest return metric at 70.3% versus its period average of 36.7%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Richard Gerald Adcock | President, Chief Executive Officer & Director | USD 1.58M | 57 | — | — |
Patrick Soon-Shiong FRCS | Founder, Executive Chairman and Global Chief Scientific & Medical Officer | USD 1.15M | 73 | — | — |
David C. Sachs | Chief Financial Officer | USD 902.17K | 48 | 40.65K | <0.01% |
Regan J. Lauer | Chief Accounting Officer | USD 522.49K | 56 | 4.07K | <0.01% |
Enrique Diloné | Chief Technology Officer | — | 59 | — | — |
Leonard S. Sender | Chief Medical Officer of Liquid Tumors & Cell Therapy | — | — | — | — |
Sandeep K. Reddy | Chief Medical Officer | — | — | — | — |
Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy | — | — | — | — |
Barry J. Simon | Chief Corporation Affairs Officer & Director | — | 61 | 2.78M | 0.27% |
Emily Arison | Senior Vice President of Human Resources | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
16
$9.51M
Net Transaction Value
−$9.51M
Net selling
Most Active
Simon Barry J.
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Oct 5, 26Oct 5, 2026 | Simon Barry J. Direct | Sell | $268.8K$268,760.00 |
| Oct 2, 26Oct 2, 2026 | Cohen Cheryl Direct | Sell | $851.1K$851,088.00 |
| Jul 2, 26Jul 2, 2026 | Cohen Cheryl Direct | Sell | $1.2M$1,246,941.11 |
| Jul 1, 26Jul 1, 2026 | Selecky Christobel Direct | Sell | $1.4M$1,439,065.68 |
| Jun 30, 26Jun 30, 2026 | Selecky Christobel Direct | Sell | $9K$9,000.00 |
| Jun 29, 26Jun 29, 2026 | Selecky Christobel Direct | Sell | $862.2K$862,215.92 |
| Jun 24, 26Jun 24, 2026 | Simon Barry J. Direct | Sell | $196.9K$196,907.50 |
| Jun 4, 26Jun 4, 2026 | Simon Barry J. Direct | Sell | $165.3K$165,305.54 |
| Feb 24, 26Feb 24, 2026 | Simon Barry J. Direct | Sell | $900.8K$900,787.50 |
| Feb 23, 26Feb 23, 2026 | Selecky Christobel Direct | Sell | $250K$250,000.00 |
1–10 of 16
Summary
Insiders reported 0 buys worth $0.00 and 16 sells worth $9.51M over the last 12 months. That adds up to net selling of $9.51M. Simon Barry J. was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +678.6% | +86.0% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +678.6% over three years. Forward estimates point to Revenue at +86.0% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does ImmunityBio, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about IBRX's management, answered from reported figures.
Who manages IBRX?
ImmunityBio, Inc. (IBRX) lists 10 active executives. The top listed executive is Enrique Diloné, Chief Technology Officer.
Are IBRX insiders buying or selling?
Recent insider activity shows net buying of $563.39M.
Continue the stock analysis
Jump to another research area for this company.